Lisa T Dooley
Overview
Explore the profile of Lisa T Dooley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Griffiths C, Strober B, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al.
N Engl J Med
. 2010 Jan;
362(2):118-28.
PMID: 20071701
Background: Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known. We compared two biologic...
2.
Papp K, Langley R, Lebwohl M, Krueger G, Szapary P, Yeilding N, et al.
Lancet
. 2008 May;
371(9625):1675-84.
PMID: 18486740
Background: Ustekinumab, a human monoclonal antibody against interleukins 12 and 23, has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of ustekinumab in psoriasis patients and...
3.
Leonardi C, Kimball A, Papp K, Yeilding N, Guzzo C, Wang Y, et al.
Lancet
. 2008 May;
371(9625):1665-74.
PMID: 18486739
Background: Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody directed against these cytokines, for the treatment of psoriasis. Methods:...
4.
Reich K, Nestle F, Wu Y, Bala M, Eisenberg D, Guzzo C, et al.
Eur J Dermatol
. 2007 Aug;
17(5):381-6.
PMID: 17673380
This study examined the impact of infliximab maintenance therapy on productivity in patients with moderate-to-severe psoriasis. Patients from the multicentre, double-blind, placebo-controlled EXPRESS study (n = 378) were randomised to...
5.
Krueger G, Langley R, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al.
N Engl J Med
. 2007 Feb;
356(6):580-92.
PMID: 17287478
Background: Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis....
6.
Menter A, Feldman S, Weinstein G, Papp K, Evans R, Guzzo C, et al.
J Am Acad Dermatol
. 2006 Nov;
56(1):31.e1-15.
PMID: 17097378
Background: Previous studies of infliximab in psoriasis have demonstrated rapid improvement with induction therapy and sustained response with regularly administered maintenance therapy. Objective: The efficacy and safety of continuous (every-8-week)...
7.
Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, et al.
J Rheumatol
. 2006 Sep;
33(11):2254-9.
PMID: 16960923
Objective: To examine the effect of infliximab on employment status, time lost from work, and productivity in a double-blind, placebo-controlled study of patients with active psoriatic arthritis (PsA). Methods: Two...
8.
Reich K, Nestle F, Papp K, Ortonne J, Evans R, Guzzo C, et al.
Lancet
. 2005 Oct;
366(9494):1367-74.
PMID: 16226614
Background: Tumour necrosis factor alpha (TNFalpha) is thought to play a part in the pathogenesis of psoriasis. We assessed the efficacy and safety of continuous treatment with infliximab, a monoclonal...
9.
Gottlieb A, Evans R, Li S, Dooley L, Guzzo C, Baker D, et al.
J Am Acad Dermatol
. 2004 Sep;
51(4):534-42.
PMID: 15389187
Background: Tumor necrosis factor-alpha is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-alpha, blocking its biologic activity. Objective:...
10.
Gottlieb A, Chaudhari U, Baker D, Perate M, Dooley L
J Drugs Dermatol
. 2003 Jul;
2(3):260-6.
PMID: 12848110
The Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA) are commonly used, but fail to measure quality of life and the patient's perception of well-being. In response...